Clinical practice guidelines for the diagnosis and treatment of cutaneous leishmaniasis in turkey

dc.contributor.authorUzun, Soner
dc.contributor.authorGurel, Mehmet S.
dc.contributor.authorDurdu, Murat
dc.contributor.authorAkyol, Melih
dc.contributor.authorKaraman, Bilge Fettahlioglu
dc.contributor.authorAksoy, Mustafa
dc.contributor.authorAytekin, Sema
dc.contributor.authorBorlu, Murat
dc.contributor.authorDogan, Esra Inan
dc.contributor.authorDogramaci, Cigdem Asena
dc.date.accessioned2019-07-09T10:24:46Z
dc.date.available2019-07-09T10:24:46Z
dc.date.issued2018
dc.departmentİnönü Üniversitesien_US
dc.description.abstractBackground Cutaneous leishmaniasis ( CL) is a vector- born parasitic disease characterized by various skin lesions that cause disfiguration if healed spontaneously. Although CL has been endemic for many years in the southern regions of Turkey, an increasing incidence in nonendemic regions is being observed due to returning travelers and, more recently, due to Syrian refugees. Thus far, a limited number of national guidelines have been proposed, but no common Turkish consensus has emerged. Objectives The aim of this study was to develop diagnostic and therapeutic guidelines for the management of CL in Turkey. Methods This guideline is a consensus text prepared by 18 experienced CL specialists who have been working for many years in areas where the disease is endemic. The Delphi method was used to determine expert group consensus. Initially, a comprehensive list of items about CL was identified, and consensus was built from feedback provided by expert participants from the preceding rounds. Results Evidence- based and expert- based recommendations through diagnostic and therapeutic algorithms according to local availability and conditions are outlined. Conclusion Because CL can mimic many other skin diseases, early diagnosis and early treatment are very important to prevent complications and spread of the disease. The fastest and easiest diagnostic method is the leishmanial smear. The most common treatment is the use of local or systemic pentavalent antimony compounds.en_US
dc.identifier.citationUzun, S .Gurel, MS .Durdu, M. Akyol, M.Karaman, BF .Aksoy, M.Aytekin, S. Borlu, M.Dogan, EI .Dogramaci, CA.(2018).Clinical practice guidelines for the diagnosis and treatment of cutaneous leishmaniasis in turkey. Cilt:57. Sayı:8. 973-982 ss.en_US
dc.identifier.endpage982en_US
dc.identifier.issue8en_US
dc.identifier.startpage973en_US
dc.identifier.urihttps://hdl.handle.net/11616/12448
dc.identifier.volume57en_US
dc.language.isoenen_US
dc.publisherWıley, 111 rıver st, hoboken 07030-5774, nj usaen_US
dc.relation.ispartofInternatıonal journal of dermatologyen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectIntralesıonal sodıum stıbogluconateen_US
dc.subjectmeglumıne antımonıateen_US
dc.subjectcryotherapyen_US
dc.subjectdonovanıen_US
dc.subjectsanlıurfaen_US
dc.subjecteffıcacyen_US
dc.subjectfeaturesen_US
dc.subjecttrıalen_US
dc.titleClinical practice guidelines for the diagnosis and treatment of cutaneous leishmaniasis in turkeyen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
makale dosyası.pdf
Boyut:
310.81 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Makale dosyası
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.71 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama: